胺替代选择性调节治疗性激素的蛋白质分解和受体活性
Xing Chen1, Elizabeth G Mietlicki-Baase2, Taylor M Barrett1
1Department of Chemistry, University of Pennsylvania , 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States.
Journal of the American Chemical Society
|November 14, 2017
概括
胺修饰增强了抗降解的稳定性,提高了治疗潜力. 这种修改为开发更有效的基于的药物和成像剂提供了一种新方法.
科学领域:
- 生物化学
- 医学化学
- 药理学
背景情况:
- 激素是有价值的治疗药物,但在体内迅速降解.
- 已经存在的突变和化学合成通常是广泛的.
- 胺化提供了一种选择性修饰策略,以提高的稳定性.
研究的目的:
- 证明胺替代在激素中的有用性.
- 增强葡萄糖类-1 (GLP-1) 和胃抑制性多 (GIP) 的稳定性.
- 调查胺化对蛋白酶相互作用和信号偏差的影响.
主要方法:
- 一个原子的O-到S修饰骨类胺化.
- 使用GLP-1和GIP作为原则证明.
- 对二甲酶4 (DPP-4) 分裂的稳定性进行了评估.
- 评估了循环AMP (cAMP) 激活和β- 止剂的功效.
主要成果:
- 与DPP-4相比,胺替代剂增加了GLP-1和GIP的稳定性高达750倍.
- 与原始相比,稳定类型显示出近等效的cAMP激活.
- GLP- 1 具有降低的β- 止剂功效,表明信号偏差发生了变化.
- 胺GLP-1类似物在老鼠体内表现出优异的血糖控制.
结论:
- 胺修饰是一种可行的策略,可以提高治疗剂的蛋白解稳定性.
- 这种方法可以选择性地调节蛋白相互作用,提高治疗效果.
- 胺为开发具有调节信号偏差和改善药理学特征的激剂提供了潜力.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
4.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
1.1K
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
1.1K
Translocation of Proteins into the Mitochondria
13.5K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
13.5K
Antihypertensive Drugs: Thiazide-Class Diuretics
1.9K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.9K
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K


